news
13th International Conference on Metabolomics and Systems Biology
Euro Metabolomics 2018 will be a platform to investigate on recent research and advancements that can be useful to the researchers.
List view / Grid view
Ion Channels
news
Nicotinic receptor research paves way for targeted dementia therapy
A new study which identifies how acetylcholine impacts learning and memory by acting at different receptors could prove significant in the drive to develop more targeted and effective therapies for dementia...
webinar
Assessing neurological ion channel therapeutic and liability targets
10 March 2017 | By Charles River
This webinar explores neurological ion channel therapeutic and liability targets, featuring four subtypes of NMDA receptors. We also discuss the rationale and options for assessment of therapeutic compounds on panels of CNS ion channels for evaluating their risk for CNS liabilities...
article
Clinical optimism for antagonists targeting certain ion channels
Adenosine triphosphate (ATP)-gated ion channels serve important neurophysiological functions and have been an attractive class of drug target for a decade...
article
Ion channels: Small molecules versus biologics – the quest for the ideal Nav1.7 inhibitor
Ion channels modulate and control many fundamental physiological processes in various tissues and alterations in their functions give rise to a wide range of pathophysiologies, which makes them important drug targets. Indeed, for decades, drugs modulating ion channel activity have been targeted by the pharmaceutical industry. Historically, however, developing drugs…
news
Research suggests ion channel blocking drugs could be used in cancer therapy
12 August 2015 | By Author: Katie Sadler, Digital Content Producer, Drug Target Review
Research carried out by University of California San Francisco (UCSF) has revealed ion channel blocking drugs could play a part in cancer therapy. The common class of channel blocking drugs, which are used to treat cardiac, neurological, and psychiatric disorders, could prove to be beneficial in cancer treatment according to…
news
MorphoSys and G7 Therapeutics to develop antibodies targeting GPCRs
4 August 2015 | By Victoria White
MorphoSys and G7 Therapeutics have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs)...
article
Antibody Discovery Technologies: the partnership between academia and biopharma in the therapeutic monoclonal antibody success story
The use of monoclonal antibodies and antibody-based molecules as therapeutics to treat patients suffering with severe disease has become a major success story. Due to the exquisite specificity with which they interact with their antigen and the fact that their large binding surface can intervene at sites and targets not…